



Immunobridging In Vaccine

- **Immunobridging** is a regulatory and scientific method where:
 - Researchers compare immune responses (e.g., antibody levels) in a new group to those from a group where **vaccine efficacy has already been proven**.
- It uses **immunological markers** to infer the effectiveness of a new drug through **a surrogate** measure of efficacy.
- If the immune response in the new group is **non-inferior or superior**, the vaccine is considered **likely effective** — even if no clinical efficacy trial was done in that group.
- It has been used (e.g., to update **human papillomavirus vaccines**) to ensure that newer vaccines can cover more strains of HPV at the right doses, or to propose simpler schedules with fewer doses.



It is a worthy alternative to difficult placebo-controlled efficacy trial